Walvax’s modular workshop for SARS-CoV-2 mRNA Vaccine, the first modular mRNA workshop in China, has been delivered
Media
Sep 7, 2021
Walvax
On September 1, 2021, Walvax’s modular workshop for SARS-CoV-2 mRNA Vaccine, was officially delivered. It is an advanced process combining modular buildings with conventionally built facilities, which allows for tighter construction and can accelerate the industrialization schedule of SARS-CoV-2 mRNA Vaccine. Construction of modular buildings can occur simultaneously with the site and foundation work, allowing projects to be completed in a shorter period.
Related Links
May 22, 2024
Walvax Participated in the Annual Investment Meeting (AIM) Congress 2024 in Abu Dhabi, UAE
Learn More
May 11, 2022
Walvax Publishes Immunogenicity and Safety Data from Phase 3 Clinical Study of PCV13 (the 2nd available 13-valent pneumococcal polysaccharide conjugate vaccine worldwide) in Frontiers in Microbiology
Learn More
Nov 13, 2022
Walvax and Etana Sign MOU for PCV and HPV Production Collaboration in Indonesia
Learn More